Have you ever experienced tingling after running a marathon? Is marathon running good for your nerves? Tune in to this episode and listen to Drs. Rubin and Shahrizaila discuss an unusual case to help you decide whether or not to take up running.
Grab your hot chocolate and cozy up to your fireplace as you warm up with an educational discussion about a patient who lost his voice. Drs. Rubin and Munin will help teach you how to help patients find their voice (or at least find some muscles contributing to their voice with needle EMG) as they figure out the best way to approach this patient.
1/30/2025-In this AANEM podcast, Dr. Stino interviews Dr. Allen on the groundbreaking ADHERE study, published in Lancet Neurology in 2024, which investigated efgartigimod for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). As the largest CIDP trial to date with 322 patients across 146 sites, it marked the first major study of a targeted biologic therapy in CIDP. The trial featured a unique two-stage design: an open-label response phase followed by a randomized controlled phase for responders. Dr. Allen explains the rationale behind targeting IgG in CIDP, despite its less clear antibody-mediated mechanism compared to myasthenia gravis. The study demonstrated a 66-70% response rate in the open-label phase, with significantly lower relapse rates compared to placebo in the randomized phase. This research represents a significant advancement in CIDP treatment options, offering a weekly subcutaneous administration that could reduce treatment burden compared to traditional therapies. 31 min.